Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro

  • Authors:
    • Yuki Yamamoto
    • Kazumasa Fukuda
    • Yasushi Fuchimoto
    • Yumi Matsuzaki
    • Yoshiro Saikawa
    • Yuko Kitagawa
    • Yasuhide Morikawa
    • Tatsuo Kuroda
  • View Affiliations

  • Published online on: July 4, 2013     https://doi.org/10.3892/or.2013.2588
  • Pages: 1081-1086
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overexpression of human epidermal growth factor receptor (EGFR) has been detected in various tumors and is associated with poor outcomes. Combination treatment regimens with EGFR-targeting and cytotoxic agents are a potential therapeutic option for rhabdomyosarcoma (RMS) with EGFR amplification. We investigated the effects of combination treatment with actinomycin D and the EGFR-targeting agent cetuximab in 4 RMS cell lines. All 4 RMS cell lines expressed wild-type K-ras, and 2 of the 4 overexpressed EGFR, as determined by flow cytometry, real-time PCR and direct sequencing. Combination of cetuximab and actinomycin D was highly effective, synergistically inhibiting cell growth with a combination index of less than 1. Moreover, combination treatment with these two reagents increased the rate of apoptosis in EGFR-positive cells. Cetuximab has antitumor activity in EGFR-amplified RMS cells when combined with antitumor reagents, indicating that cetuximab is a potential therapeutic reagent for RMS with EGFR amplification.
View Figures
View References

Related Articles

Journal Cover

September 2013
Volume 30 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamamoto Y, Fukuda K, Fuchimoto Y, Matsuzaki Y, Saikawa Y, Kitagawa Y, Morikawa Y and Kuroda T: Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro. Oncol Rep 30: 1081-1086, 2013.
APA
Yamamoto, Y., Fukuda, K., Fuchimoto, Y., Matsuzaki, Y., Saikawa, Y., Kitagawa, Y. ... Kuroda, T. (2013). Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro. Oncology Reports, 30, 1081-1086. https://doi.org/10.3892/or.2013.2588
MLA
Yamamoto, Y., Fukuda, K., Fuchimoto, Y., Matsuzaki, Y., Saikawa, Y., Kitagawa, Y., Morikawa, Y., Kuroda, T."Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro". Oncology Reports 30.3 (2013): 1081-1086.
Chicago
Yamamoto, Y., Fukuda, K., Fuchimoto, Y., Matsuzaki, Y., Saikawa, Y., Kitagawa, Y., Morikawa, Y., Kuroda, T."Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro". Oncology Reports 30, no. 3 (2013): 1081-1086. https://doi.org/10.3892/or.2013.2588